Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Are plasma markers for Alzheimer’s disease ready for clinical use?

Plasma biomarkers pertaining to the underlying pathophysiology of Alzheimer’s disease have recently become available (for example, amyloid beta and phosphorylated tau). The utility of these markers poses a question for clinicians (now and in the future): are plasma biomarkers for Alzheimer’s disease are ready for clinical use at this time?

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Potential evaluation pathway for a patient being considered for treatment with a disease-modifying therapy for Alzheimer’s disease.


  1. Jack, C. R. Jr. et al. Alzheimers Dement. 14, 535–562 (2018).

    Article  Google Scholar 

  2. Dubois, B. et al. Lancet Neurol. 20, 484–496 (2021).

    Article  CAS  Google Scholar 

  3. West, T. et al. Mol. Neurodegener. 16, 30 (2021).

    Article  CAS  Google Scholar 

  4. Karikari, T. K. et al. Lancet Neurol. 19, 422–433 (2020).

    Article  CAS  Google Scholar 

  5. Janelidze, S. et al. Nat. Med. 26, 379–386 (2020).

    Article  CAS  Google Scholar 

  6. Barthélemy, N. R. et al. Nat. Med. 26, 398–407 (2020).

    Article  Google Scholar 

  7. Palmqvist, S. et al. J. Am. Med. Assoc. 324, 772–781 (2020).

    Article  CAS  Google Scholar 

  8. Cullen, N. C. et al. Nat. Aging 1, 114–123 (2021).

    Google Scholar 

  9. Palmqvist, S. et al. Nat. Med. 27, 1034–1042 (2021).

    Article  CAS  Google Scholar 

  10. Ossenkoppele, R. et al. EMBO Mol. Med. 13, e14398 (2021).

    Article  CAS  Google Scholar 

  11. Cummings, J. et al. J. Prev. Alzheimers Dis. 8, 398–410 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Mintun, M. A. et al. N. Engl. J. Med. 384, 1691–1704 (2021).

    Article  CAS  Google Scholar 

  13. Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H. & Blennow, K. JAMA Neurol. 76, 791–799 (2019).

    Article  Google Scholar 

  14. Morris, J. C. et al. JAMA Neurol. 76, 264–273 (2019).

    Article  Google Scholar 

  15. Gauthier, S., Therriault, J., Pascoal, T. & Rosa-Neto, P. Expert Rev. Neurother. 20, 1211–1213 (2020).

    Article  CAS  Google Scholar 

  16. Petersen, R. C. Neurology 91, 395–402 (2018).

    Article  Google Scholar 

Download references


Funding was provided by NIH National Institute on Aging P30 AG062677 and U01 AG006786.

Author information

Authors and Affiliations



R.C.P. is the sole author of this Comment.

Corresponding author

Correspondence to Ronald C. Petersen.

Ethics declarations

Competing interests

R.C.P. has consulted for Roche, Inc., Merck, Inc., Biogen, Inc., Eisai, Inc. and Nestle, Inc., and served on a DSMB for Genentech, Inc. R.C.P. has received grants from the National Institute on Aging, the GHR Foundation and the Alzheimer’s Association.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Petersen, R.C. Are plasma markers for Alzheimer’s disease ready for clinical use?. Nat Aging 2, 94–96 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research